Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Zimran

Showing results (151-160 of 238) with videos related to

Pageof 24
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 13, 2006
Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher diseaseRichard J Wenstrup, Katherine A Kacena, Paige Kaplan, et al.
Blood Cells, Molecules & Diseases|November 15, 2016
Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome surveyHeather Lau, Nadia Belmatoug, Patrick Deegan, et al.
American Journal of Hematology|February 18, 2026
Excess Risk of Monoclonal Gammopathy in Patients With Gaucher DiseaseMajdolen Istaiti, Katie Thoren, Dickran Kazandjian, et al.
Orphanet Journal of Rare Diseases|January 29, 2025
Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome SurveyAri Zimran, Shoshana Revel-Vilk, Tama Dinur, et al.
Molecular Genetics and Metabolism|April 9, 2011
A safety trial of high dose glyceryl triacetate for Canavan diseaseReeval Segel, Yair Anikster, Shoshana Zevin, et al.
American Journal of Hematology|February 24, 2018
Glucosylsphingosine is a reliable response biomarker in Gaucher diseaseDavid Arkadir, Tama Dinur, Shoshana Revel-Vilk, et al.
Systematic Reviews|April 22, 2017
Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant dataTatiana Raskovalova, Patrick B Deegan, Ruby Yang, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 6, 2007
Monitoring of Gaucher patients with a novel chitotriosidase assayAricha Schoonhoven, Bernard Rudensky, Debbie Elstein, et al.
Molecular Genetics and Metabolism|September 12, 2016
Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher diseaseDeborah Elstein, T Andrew Burrow, Joel Charrow, et al.
Blood|March 20, 2010
Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experienceAri Zimran, Gheona Altarescu, Mici Philips, et al.
Pageof 24

Showing results (151-160 of 238) with videos related to

Sort By:
Pageof 24
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 13, 2006
Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher diseaseRichard J Wenstrup, Katherine A Kacena, Paige Kaplan, et al.
Blood Cells, Molecules & Diseases|November 15, 2016
Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome surveyHeather Lau, Nadia Belmatoug, Patrick Deegan, et al.
American Journal of Hematology|February 18, 2026
Excess Risk of Monoclonal Gammopathy in Patients With Gaucher DiseaseMajdolen Istaiti, Katie Thoren, Dickran Kazandjian, et al.
Orphanet Journal of Rare Diseases|January 29, 2025
Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome SurveyAri Zimran, Shoshana Revel-Vilk, Tama Dinur, et al.
Molecular Genetics and Metabolism|April 9, 2011
A safety trial of high dose glyceryl triacetate for Canavan diseaseReeval Segel, Yair Anikster, Shoshana Zevin, et al.
American Journal of Hematology|February 24, 2018
Glucosylsphingosine is a reliable response biomarker in Gaucher diseaseDavid Arkadir, Tama Dinur, Shoshana Revel-Vilk, et al.
Systematic Reviews|April 22, 2017
Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant dataTatiana Raskovalova, Patrick B Deegan, Ruby Yang, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 6, 2007
Monitoring of Gaucher patients with a novel chitotriosidase assayAricha Schoonhoven, Bernard Rudensky, Debbie Elstein, et al.
Molecular Genetics and Metabolism|September 12, 2016
Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher diseaseDeborah Elstein, T Andrew Burrow, Joel Charrow, et al.
Blood|March 20, 2010
Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experienceAri Zimran, Gheona Altarescu, Mici Philips, et al.
Pageof 24